110 related articles for article (PubMed ID: 2465816)
1. Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer.
Matzkin H; Lewyshon O; Ayalon D; Braf Z
Cancer; 1989 Apr; 63(7):1287-91. PubMed ID: 2465816
[TBL] [Abstract][Full Text] [Related]
2. Use of gonadotropin-releasing hormone analogue in advanced prostatic cancer: 3 years clinical experience.
Matzkin H; Greenstein A; Kaver I; Braf Z
Isr J Med Sci; 1989 Jul; 25(7):388-92. PubMed ID: 2474522
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen. Monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker.
Dundas GS; Porter AT; Venner PM
Cancer; 1990 Jul; 66(1):45-8. PubMed ID: 1693877
[TBL] [Abstract][Full Text] [Related]
4. Comparison of prostate-specific antigen and prostatic acid phosphatase in the management of prostatic cancer.
Turkes A; Nott J; Turkes AO; Griffiths K
Am J Clin Oncol; 1988; 11 Suppl 2():S77-9. PubMed ID: 2468280
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
[TBL] [Abstract][Full Text] [Related]
6. Value of biochemical markers in the management of disseminated prostatic cancer.
Mulders PF; Fernandez del Moral P; Theeuwes AG; Oosterhof GO; van Berkel HT; Debruyne FM
Eur Urol; 1992; 21(1):2-5. PubMed ID: 1376692
[TBL] [Abstract][Full Text] [Related]
7. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
Csapo Z; Brand K; Walther R; Fokas K
J Urol; 1988 Nov; 140(5):1032-8. PubMed ID: 2459419
[TBL] [Abstract][Full Text] [Related]
8. [Role of the markers PAP-PSA in the diagnosis of cancer of the prostate].
Petrone U; Gaspari G; Marascia G; Magnocavallo N; Petrone D; Tucci C
Minerva Urol Nefrol; 1990; 42(2):73-5. PubMed ID: 1697431
[TBL] [Abstract][Full Text] [Related]
9. Prostate tumour markers as an aid in the staging of prostatic cancer.
Haapiainen RK; Permi EJ; Rannikko SA; Voutilainen PE; Liewendahl K; Stenman UH; Alfthan OS
Br J Urol; 1990 Mar; 65(3):264-7. PubMed ID: 1692497
[TBL] [Abstract][Full Text] [Related]
10. Immunologically measured serum markers and their role in the management of prostate cancer.
Powell P; Neal D; Gibb I; Wilson L; Hall R
Eur Urol; 1988; 15(1-2):48-53. PubMed ID: 2463921
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer.
Mannini D; Maver P; Aiello E; Corrado G; Vecchi F; Bellanova B; Marengo M
Urol Res; 1988; 16(1):9-12. PubMed ID: 2449758
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
[TBL] [Abstract][Full Text] [Related]
13. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
Morote Robles J; de Torres Mateos JA
Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
[TBL] [Abstract][Full Text] [Related]
14. Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions.
Tarle M
Anticancer Res; 1988; 8(4):569-72. PubMed ID: 2460018
[TBL] [Abstract][Full Text] [Related]
15. Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.
Huhtaniemi I; Nikula H; Rannikko S
J Clin Endocrinol Metab; 1985 Oct; 61(4):698-704. PubMed ID: 2993345
[TBL] [Abstract][Full Text] [Related]
16. [Clinical studies on tumor markers for monitoring prostate cancer patients; the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and gamma-seminoprotein].
Shinoda I
Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2627-39. PubMed ID: 1703555
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone.
Waxman JH; Wass JA; Hendry WF; Whitfield HN; Bary P; Besser GM; Malpas JS; Oliver RT
Br J Urol; 1983 Dec; 55(6):737-42. PubMed ID: 6418264
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
19. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J
Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713
[TBL] [Abstract][Full Text] [Related]
20. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
